Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.

Gandara, David R; Paul, Sarah M; Kowanetz, Marcin; Schleifman, Erica; Zou, Wei; Li, Yan; Rittmeyer, Achim; Fehrenbacher, Louis; Otto, Geoff; Malboeuf, Christine; Lieber, Daniel S; Lipson, Doron; Silterra, Jacob; Amler, Lukas; Riehl, Todd; Cummings, Craig A; Hegde, Priti S; Sandler, Alan; Ballinger, Marcus; Fabrizio, David; Mok, Tony; Shames, David S

Gandara, David R; Paul, Sarah M; Kowanetz, Marcin; Schleifman, Erica; Zou, Wei; Li, Yan; Rittmeyer, Achim; Fehrenbacher, Louis; Otto, Geoff; Malboeuf, Christine; Lieber, Daniel S; Lipson, Doron; Silterra, Jacob; Amler, Lukas; Riehl, Todd; Cummings, Craig A; Hegde, Priti S; Sandler, Alan; Ballinger, Marcus; Fabrizio, David; Mok, Tony; Shames, David S.

Affiliation

Gandara DR; UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. drgandara@ucdavis.edu.
Paul SM; Genentech, Inc., San Francisco, CA, USA.
Kowanetz M; Genentech, Inc., San Francisco, CA, USA.
Schleifman E; Genentech, Inc., San Francisco, CA, USA.
Zou W; Genentech, Inc., San Francisco, CA, USA.
Li Y; Genentech, Inc., San Francisco, CA, USA.
Rittmeyer A; Lungenfachklinik Immenhausen, Immenhausen, Germany.
Fehrenbacher L; Kaiser Permanente Medical Center, Vallejo, CA, USA.
Otto G; Foundation Medicine, Inc., Cambridge, MA, USA.
Malboeuf C; Foundation Medicine, Inc., Cambridge, MA, USA.
Lieber DS; Foundation Medicine, Inc., Cambridge, MA, USA.
Lipson D; Foundation Medicine, Inc., Cambridge, MA, USA.
Silterra J; Foundation Medicine, Inc., Cambridge, MA, USA.
Amler L; Genentech, Inc., San Francisco, CA, USA.
Riehl T; Genentech, Inc., San Francisco, CA, USA.
Cummings CA; Genentech, Inc., San Francisco, CA, USA.
Hegde PS; Genentech, Inc., San Francisco, CA, USA.
Sandler A; Genentech, Inc., San Francisco, CA, USA.
Ballinger M; Genentech, Inc., San Francisco, CA, USA.
Fabrizio D; Foundation Medicine, Inc., Cambridge, MA, USA.
Mok T; State Key Laboratory of Southern China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China. tony@clo.cuhk.edu.hk.
Shames DS; Genentech, Inc., San Francisco, CA, USA. shames.david@gene.com.

Nat Med ; 24(9): 1441-1448, 2018 09.

Article de En | MEDLINE | ID: mdl-30082870

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome pulmonaire non à petites cellules / Charge tumorale / Tumeurs du poumon / Anticorps monoclonaux / Mutation Type d'étude: Clinical_trials / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Nat Med Sujet du journal: BIOLOGIA MOLECULAR / MEDICINA Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google